#1 Clinical Trials Search in Europe

Mosunetuzumab

Mosunetuzumab is an innovative bispecific antibody being studied in clinical trials for the treatment of different types of lymphomas and other conditions. This article summarizes key information about ongoing clinical trials evaluating mosunetuzumab’s safety and efficacy in various patient populations and disease settings.

Table of Contents

What is Mosunetuzumab?

Mosunetuzumab is a new type of cancer treatment that belongs to a class of drugs called bispecific antibodies. It is also known by other names such as RO7030816, BTCT4465A, and Lunsumio[1][2]. This medication is designed to help your immune system fight certain types of blood cancers, particularly those affecting B-cells, which are a type of white blood cell[3].

How Does Mosunetuzumab Work?

Mosunetuzumab works in a unique way. It has been engineered to attach to two different types of cells in your immune system:

  • T-cells: These are immune cells that normally help fight infections and cancer.
  • Cancerous B-cells: These are the abnormal cells in certain types of blood cancers.

By attaching to both of these cell types, mosunetuzumab acts like a bridge, bringing the T-cells close to the cancerous B-cells. This helps direct your T-cells to recognize and attack the cancer cells[3]. This innovative approach is part of a broader category of treatments called immunotherapy, which harnesses your body’s own immune system to fight cancer.

Conditions Treated with Mosunetuzumab

Mosunetuzumab is being studied for the treatment of several types of blood cancers, including:

  • Follicular Lymphoma (FL): This is a slow-growing type of non-Hodgkin lymphoma that affects B-cells[1][2].
  • Diffuse Large B-cell Lymphoma (DLBCL): This is a more aggressive type of non-Hodgkin lymphoma[3].
  • Marginal Zone Lymphoma (MZL): Another type of slow-growing non-Hodgkin lymphoma[1].
  • B-cell Acute Lymphoblastic Leukemia (B-ALL): A type of blood cancer that affects B-cells[4].

Many of the clinical trials are focusing on patients whose cancer has either come back after previous treatment (relapsed) or has not responded well to other treatments (refractory)[2][3].

How is Mosunetuzumab Administered?

Mosunetuzumab is typically given in one of two ways:

  1. Intravenous (IV) infusion: The medication is given directly into a vein.
  2. Subcutaneous (SC) injection: The medication is injected under the skin, usually in the abdomen area.

The dosing schedule often follows a “step-up” approach, where the first dose is lower and subsequent doses are increased. For example, a common schedule might be:

  • Cycle 1, Day 1: 5 mg
  • Cycle 1, Day 8: 45 mg
  • Cycle 1, Day 15: 45 mg
  • Cycles 2 through 8, Day 1: 45 mg

Each cycle typically lasts 21 or 28 days[1][2]. The exact dosing and schedule may vary depending on the specific clinical trial or treatment plan.

Current Clinical Trials

Mosunetuzumab is currently being studied in several clinical trials for different conditions and in various combinations with other treatments. Some notable trials include:

  • A study for newly diagnosed follicular lymphoma[1].
  • A trial for follicular lymphoma that has relapsed within 24 months of starting first-line treatment[2].
  • A study combining mosunetuzumab with polatuzumab vedotin for untreated follicular lymphoma[10].
  • A trial exploring mosunetuzumab as a consolidation therapy after stem cell transplant for aggressive B-cell lymphomas[3].
  • A study for relapsed or refractory B-cell acute lymphoblastic leukemia[4].

Potential Side Effects

As with any medication, mosunetuzumab can cause side effects. Some of the potential side effects being monitored in clinical trials include:

  • Cytokine Release Syndrome (CRS): This is a condition where the immune system becomes highly activated, potentially causing fever, chills, and other flu-like symptoms[2].
  • Neurological effects: Some patients may experience confusion, headaches, or other neurological symptoms[3].
  • Infections: Because mosunetuzumab affects the immune system, it may increase the risk of infections[1].

It’s important to note that clinical trials closely monitor patients for these and other potential side effects to ensure safety[1][2][3].

Combination Therapies

Researchers are also exploring how mosunetuzumab works when combined with other cancer treatments. Some combinations being studied include:

  • Mosunetuzumab + Lenalidomide: This combination is being tested in patients with follicular lymphoma[6].
  • Mosunetuzumab + Polatuzumab Vedotin: This combination is being studied for untreated follicular lymphoma[10].
  • Mosunetuzumab + Zanubrutinib: This combination is being explored for various types of lymphoma[5][9].
  • Mosunetuzumab + Tazemetostat: This combination is being tested in untreated follicular lymphoma[9].

These combination therapies aim to enhance the effectiveness of treatment while managing potential side effects.

Aspect Details
Drug Name Mosunetuzumab (also known as RO7030816, BTCT4465A, Lunsumio)
Drug Type Bispecific antibody targeting CD3 on T cells and CD20 on B cells
Main Indications Various B-cell lymphomas (follicular, diffuse large B-cell, marginal zone)
Administration Intravenous (IV) infusion or subcutaneous (SC) injection
Dosing Strategy Often uses a “step-up” dosing approach to minimize side effects
Key Outcomes Measured Safety, efficacy (response rates), survival outcomes (PFS, OS)
Common Side Effects Cytokine release syndrome, infusion-related reactions
Combination Therapies Being studied with other drugs like lenalidomide and zanubrutinib
Trial Phases Mostly Phase 1 and 2 studies ongoing
Patient Populations Both newly diagnosed and relapsed/refractory patients

FAQ

  • What is mosunetuzumab? Mosunetuzumab is a bispecific antibody designed to attach to two targets in the immune system: T cells and cancerous B cells. It directs T cells to kill the cancerous B cells.
  • What types of cancer is mosunetuzumab being studied for? Mosunetuzumab is being evaluated in clinical trials for various lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, and B-cell acute lymphoblastic leukemia.
  • How is mosunetuzumab administered? Mosunetuzumab can be given as an intravenous (IV) infusion or as a subcutaneous (SC) injection under the skin, depending on the specific trial protocol.
  • What are some potential side effects of mosunetuzumab? Common side effects being monitored include cytokine release syndrome (CRS) and other immune-related reactions. Tocilizumab may be given to manage CRS if needed.
  • How long do mosunetuzumab clinical trials typically last? The duration varies, but many trials involve treatment cycles lasting several months, followed by a period of follow-up that can extend 2-5 years to assess long-term outcomes.

Ongoing Clinical Trials on Mosunetuzumab

  • Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Spain

  • Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark Finland Norway Sweden

Glossary

  • Bispecific antibody: A type of engineered antibody that can bind to two different targets simultaneously, in this case T cells and cancerous B cells.
  • Cytokine release syndrome (CRS): A side effect that can occur with some cancer treatments, causing symptoms like fever, nausea, and difficulty breathing due to an overactive immune response.
  • Follicular lymphoma: A common type of slow-growing non-Hodgkin lymphoma that develops from B lymphocytes.
  • Diffuse large B-cell lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that grows and spreads quickly.
  • Marginal zone lymphoma: A slow-growing type of B-cell non-Hodgkin lymphoma that typically originates in the marginal zone of lymphoid tissue.
  • Complete response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial response (PR): A decrease in tumor size or extent of cancer in the body in response to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT06569680
  2. https://clinicaltrials.gov/study/NCT05849857
  3. https://clinicaltrials.gov/study/NCT05412290
  4. https://clinicaltrials.gov/study/NCT05961696
  5. https://clinicaltrials.gov/study/NCT05389293
  6. https://clinicaltrials.gov/study/NCT04246086
  7. https://clinicaltrials.gov/study/NCT05155345
  8. https://clinicaltrials.gov/study/NCT06563505
  9. https://clinicaltrials.gov/study/NCT05994235
  10. https://clinicaltrials.gov/study/NCT05410418